ArticlesEffect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study
Introduction
Chronic obstructive pulmonary disease (COPD) is characterised by airflow limitation, and pathophysiologically involves many components including mucus hypersecretion, oxidative stress, and inflammation in the airway and lungs.1 Therefore, agents active with mucolytic, anti-inflammatory, and antioxidative effects could offer promise for treatment.
In Europe and Asia, mucolytics such as carbocisteine have been widely used for treatment of respiratory diseases with phlegm production2 because of their capacity to facilitate sputum elimination.3, 4 Furthermore, carbocisteine seems likely to have a role in antioxidation5, 6 and anti-inflammation7, 8, 9 that might be more important than mucolysis itself for long-term management of COPD. Clinical studies have shown benefits in preventing exacerbation of COPD with carbocisteine.10, 11, 12 However, these results have been inconclusive because of certain pitfalls in study design, such as small sample size, not being double-blinded, lack of placebo control, or short period of study.13 Poole and Black14 did a systematic review of mucolytics in COPD, which has been updated15 with inclusion of the BRONCUS study16 using N-acetylcysteine. Their results showed that mucolytics including carbocisteine were effective in reducing the number of exacerbations in COPD and improving health status in all studies except BRONCUS.16 Since evidence on long-term efficacy remains insufficient, mucolytics are not recommended for regular treatment by guidelines such as that of the Global Initiative for Chronic Obstructive Lung Disease (GOLD).1 Clinical trials that closely follow reliable research study designs are therefore warranted to clarify whether COPD patients can benefit from protracted mucolytic therapy.
The aim of this study was to assess the effectiveness in preventing exacerbation, improving quality of life, as well as the safety profiles of long-term (1-year) carbocisteine administration in patients with COPD.
Section snippets
Patients
Participants were eligible for inclusion if they were diagnosed as having COPD with a postbronchodilator forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) ratio (FEV1/FVC) of less than 0·70 and an FEV1 between 25% and 79% of predicted value. The severity of COPD was defined in accordance with GOLD criteria.1 Patients had to be aged between 40 and 80 years, have a history of at least two COPD exacerbations within the previous 2 years, yet have remained clinically stable for
Results
Recruitment ran from June 1 to Sept 30, 2005, and the study was completed by Oct 15, 2006. 709 patients underwent randomisation (figure 1). Of these, two patients (one in each group) were excluded because of ineligibility, but were included in the safety analysis. Non-significant difference was found in the withdrawal rate between these two groups (13·60% vs 12·15%, χ2=0·332; p=0·565).
The two groups were similar in patient demographics, including history of smoking, duration and severity of
Discussion
The results of our study support previous findings that long-term use of carbocisteine reduced the rate of exacerbations of COPD. The advantage of carbocisteine over placebo in prevention of an exacerbation was noteworthy, even after adjustment for COPD severity and concomitant therapy. We found no difference in exacerbation rate between the carbocisteine group and placebo group at early treatment (3 month), suggesting that longer use of carbocisteine was more effective for preventing
References (29)
- et al.
Phenylalanine hydroxylase: possible involvement in the S-oxidation of S-carboxymethyl-L-cysteine
Anal Biochem
(2004) - et al.
Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys)
Eur J Pharmacol
(2004) - et al.
S-carboxymethylcysteine inhibits neutrophil activation mediated by N-formyl-methyl-leucyl-phenylalanine
Eur J Pharmacol
(2002) - et al.
Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial
Lancet
(2005) - et al.
The efficacy and safety of combination salmeterol (50 μg)/fluticasone propionate (500 μg) inhalation twice daily via accuhalar in Chinese patients with COPD
Chest
(2007) Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease GOLD website
- et al.
Long lasting effects of theology and clearance of bronchial mucus after short-term administration of high does of carbocisteine-lysine to patients with chronic bronchitis
Respiration
(1990) - et al.
Reversibility of mucociliary clearance chronic sinusitis
Clin Otolaryngol
(1985) - et al.
S-CMC-Lys-dependent stimulation of electrogenic glutathione secretion by human respiratory epithelium
J Mol Med
(2006) - et al.
The sulphoxidation of S-carboxymethyl-L-cysteine in COPD
Eur Respir J
(2006)
Carbocysteine lysine salt monohydrate (SCMC-LYS) is a selective scavenger of reactive oxygen intermediates (ROIs)
Eur Cytoline Netw
Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial
Respiration
Carbocysteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease
J Am Geriatr Soc
Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease
J Am Geriatr Soc
Cited by (317)
Therapeutic effect of phycocyanin on chronic obstructive pulmonary disease in mice
2024, Journal of Advanced ResearchTreatment of carbocysteine wastewater by bipolar membrane electrodialysis: From lab-to pilot-scale
2023, Journal of Membrane ScienceAnti-inflammatory effects of medications used for viral infection-induced respiratory diseases
2023, Respiratory InvestigationScavengome of an antioxidant
2023, Vitamins and HormonesA stepwise one-pot synthesis of aliphatic thiols and their derivatives from acrylamides and sulfur
2022, Organic and Biomolecular ChemistryContribution of small airway inflammation to the development of COPD
2024, BMC Pulmonary Medicine